Mallinckrodt Names Christiana Stamoulis as President and Chief Financial Officer
Rhea-AI Summary
Mallinckrodt (MNK) has appointed Christiana Stamoulis as President and Chief Financial Officer, effective September 22, 2025. Stamoulis, currently EVP and CFO at Incyte, will succeed Bryan Reasons, who is departing to pursue other opportunities.
With approximately 30 years of biotechnology industry experience, Stamoulis brings extensive expertise in strategy, finance, and corporate development. Her appointment follows Mallinckrodt's recent merger with Endo, marking a significant transformation period for the company. In her new role, she will oversee the finance organization and lead corporate development initiatives.
Prior to Incyte, Stamoulis held leadership positions at Unum Therapeutics, Vertex Pharmaceuticals, and served as Managing Director at Citigroup's Investment Banking division. She holds two BS degrees and an MBA from MIT.
Positive
- Strategic appointment of seasoned executive with 30 years of biotech industry experience
- Addition of strong M&A and strategic partnership expertise through new CFO
- Recent completion of merger with Endo strengthens company's market position
Negative
- Departure of current CFO Bryan Reasons creates potential transition risks
Insights
Stamoulis brings M&A expertise to Mallinckrodt at critical post-merger phase; appointment signals focus on strategic partnerships and corporate development.
Mallinckrodt's appointment of Christiana Stamoulis as President and CFO represents a strategic leadership enhancement at a pivotal transformation point. The timing is particularly significant, coming immediately after Mallinckrodt's merger with Endo, creating what appears to be a substantially transformed pharmaceutical entity.
Stamoulis brings exceptional credentials to this dual leadership role. Her approximately 30 years of biotechnology industry experience, particularly her background in corporate development at Incyte and Vertex Pharmaceuticals, positions her ideally to drive Mallinckrodt's strategic initiatives. Her investment banking experience at Citigroup and Goldman Sachs adds sophisticated financial expertise that will be crucial for navigating the post-merger integration.
What's most telling about this appointment is that Stamoulis will oversee not just finance but also corporate development initiatives. This expanded scope suggests Mallinckrodt is prioritizing strategic growth through partnerships and M&A following the Endo merger. Given her extensive experience in structuring and executing strategic partnerships, the company appears to be positioning for additional strategic transactions.
CEO Olafsson's characterization of this as a "historic moment" in the company's transformation and the emphasis on "forging a new future" indicates this leadership change is part of a broader strategic pivot. The company is clearly signaling to the market that it has ambitions beyond merely integrating Endo's operations and is actively preparing for its next phase of strategic development.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Ms. Stamoulis will join Mallinckrodt from Incyte, a leading biopharmaceutical company focused on the discovery, development, and commercialization of proprietary therapeutics. In addition to overseeing the finance organization, she will lead Mallinckrodt's corporate development initiatives, leveraging her deep industry expertise and extensive experience in strategic planning, as well as in originating, structuring, and executing strategic partnerships and M&A transactions.
"We are excited to have Christiana join Mallinckrodt at this historic moment in our transformation," said Siggi Olafsson, Mallinckrodt's President and Chief Executive Officer. "With the completion last week of our merger with Endo, we are forging a new future for our Company and adding talented new leadership to an already strong executive team. Christiana has an exceptional record of achievement in strategy, finance, corporate development, and execution, and we have every expectation that she will make significant contributions to our growth and continued success."
Ms. Stamoulis has approximately 30 years of experience in the biotechnology industry. Prior to Incyte, she was President and CFO of Unum Therapeutics and, before that role, served as Senior Vice President of Corporate Strategy and Business Development at Vertex Pharmaceuticals. Prior to Vertex, Ms. Stamoulis spent nearly 15 years as an investment banker and management consultant, serving as a Managing Director in Citigroup's Investment Banking division and a senior investment banker in the Healthcare Investment Banking Group at Goldman Sachs. She began her career as a strategy consultant at Boston Consulting Group.
"Mallinckrodt has a unique opportunity to reinvent itself following the merger with Endo, and I am honored by the opportunity to join the company at this pivotal point and contribute to the Company's new future," said Ms. Stamoulis.
Ms. Stamoulis currently serves on the Board of Directors of Hologic Inc., a medical technology company. She holds two Bachelor of Science degrees from the Massachusetts Institute of Technology (MIT) and an MBA from the MIT Sloan School of Management.
About Mallinckrodt
Mallinckrodt is a leading provider of life-enhancing therapeutics focused on addressing unmet patient needs and a world-class manufacturer of high-quality generics, sterile injectables, and active pharmaceutical ingredients.
Our company consists of multiple wholly owned subsidiaries that operate in two businesses. Our Brands business is focused on autoimmune and rare diseases in areas including endocrinology, gastroenterology, hepatology, neonatal respiratory critical care, nephrology, neurology, pulmonology, ophthalmology, orthopedics, rheumatology, and urology. Our Par Health business includes generic drugs, sterile injectables, and active pharmaceutical ingredients. To learn more, visit www.MNK-Endo.com.
Mallinckrodt uses its website as a channel of distribution of important company information, such as press releases, investor presentations and other financial information. It also uses its website to expedite public access to time-critical information regarding the Company in advance of or in lieu of distributing a press release or a filing with the U.S. Securities and Exchange Commission ("SEC") disclosing the same information. Therefore, investors should look to the Investor Relations page of the website for important and time-critical information. Visitors to the website can also register to receive automatic e-mail and other notifications alerting them when new information is made available on the Investor Relations page of the website.
Contacts
Investors
Juan Avendano
862-240-8194
avendano.juan@endo.com
Media
Michael Freitag / Aura Reinhard / Catherine Simon
Joele Frank, Wilkinson Brimmer Katcher
212-355-4449
Mallinckrodt, the "M" brand mark, the Mallinckrodt Pharmaceuticals logo, Endo and the Endo logo are trademarks owned or licensed by a Mallinckrodt company. Other brands are trademarks of a Mallinckrodt company or their respective owners. © 2025.
View original content to download multimedia:https://www.prnewswire.com/news-releases/mallinckrodt-names-christiana-stamoulis-as-president-and-chief-financial-officer-302522701.html
SOURCE Mallinckrodt plc